Holen Sie sich die Stockscreener-App
9.51
8.73%
-0.91
Handel nachbörslich:
9.40
-0.11
-1.16%
Schlusskurs vom Vortag:
$10.42
Offen:
$9.9372
24-Stunden-Volumen:
16,894
Relative Volume:
0.12
Marktkapitalisierung:
$8.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.93M
KGV:
-0.0357
EPS:
-266.137
Netto-Cashflow:
$-15.87M
1W Leistung:
+10.45%
1M Leistung:
+8.07%
6M Leistung:
+31.99%
1J Leistung:
-95.29%
1-Tages-Spanne:
$9.28
$10.25
1-Wochen-Bereich:
$8.20
$11.28
52-Wochen-Spanne:
$6.1478
$468.44
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Vergleichen Sie RNAZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
9.51 | 9.55M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
TransCode Therapeutics and Quantum Leap Collaborate on Colorectal Cancer Trial Targeting Metastatic Disease - citybuzz
TransCode and Quantum Leap to test cancer therapy in phase 2a trial By Investing.com - Investing.com South Africa
TransCode Therapeutics and Quantum Leap Healthcare Collaborative launch a phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's phase 1 trial - marketscreener.com
TransCode Therapeutics Announces Phase 2a Trial Collaboration - TradingView
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - PR Newswire
Buyout Rumor: Why hedge funds are buying NETSTREIT Corp. stockInsider Selling & Expert Curated Trade Ideas - moha.gov.vn
Critical Comparison: TransCode Therapeutics (NASDAQ:RNAZ) & ReNeuron Group (OTCMKTS:RNUGF) - Defense World
Will TransCode Therapeutics Inc. stock see PE expansion2025 Growth vs Value & Low Risk Profit Maximizing Plans - Newser
Is TransCode Therapeutics Inc. stock supported by strong cash flows2025 Top Gainers & AI Enhanced Execution Alerts - Newser
Alzamend Neuro (ALZN) Stock Analysis Report | Financials & Insights - Benzinga
Why TransCode Therapeutics Inc. stock is favored by top institutionsFed Meeting & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - MSN
Is TransCode Therapeutics Inc. stock a contrarian buyRecession Risk & Technical Pattern Recognition Alerts - newser.com
TransCode Therapeutics, Inc. (RNAZ) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
MSN Money - MSN
Real time breakdown of TransCode Therapeutics Inc. stock performanceEarnings Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
What technical models suggest about TransCode Therapeutics Inc.’s comeback2025 Dividend Review & Accurate Buy Signal Alerts - newser.com
Can TransCode Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Is TransCode Therapeutics Inc. stock resilient to inflationMarket Risk Summary & Long-Term Capital Growth Ideas - newser.com
TransCode Therapeutics Inc. recovery potential after sell offQuarterly Earnings Summary & Long-Term Capital Growth Ideas - newser.com
Will TransCode Therapeutics Inc. stock outperform value stocks2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Avidity Biosciences Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why retail investors favor TransCode Therapeutics Inc. stockWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
Market reaction to TransCode Therapeutics Inc.’s recent news - newser.com
TransCode Therapeutics appoints Michel Janicot as development officer By Investing.com - Investing.com Nigeria
TransCode Therapeutics Appoints Dr. Michel Janicot as Senior Development Officer - citybiz
TransCode Therapeutics appoints Michel Janicot as development officer - Investing.com India
Transcode Therapeutics expands executive team with appointment of Dr. Michel Janicot as Senior Development Officer - marketscreener.com
Transcode Therapeutics Expands Executive Team With Appointment Of Dr. Michel Janicot As Senior Development Officer - TradingView
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer - WV News
Is a relief rally coming for TransCode Therapeutics Inc. holders2025 Earnings Surprises & Capital Efficiency Focused Strategies - newser.com
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):